NCT00638911已完成不适用
PMS Assessing the Safety and Efficacy of Telmisartan in Patients With Mild-to-moderate Essential Hypertension
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33,247
- 主要终点
- Primary Endpoints will be the change from baseline in mean systolic blood pressure.
研究概览
简要总结
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use after market launch.
详细描述
Study 502.465(NCT00638911) was planned and conducted as 6 independent substudies with varying country participation. One study database, a data management plan or a TSAP were not planned and do not exist which precludes baseline and outcome analyses.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Primary Endpoints will be the change from baseline in mean systolic blood pressure.
时间窗: 4-24 Weeks
次要结局
- Secondary Endpoints are clinical control of the BP and response rate.(4-24 Weeks)
- Other secondary Endpoints will be discontinuations and tolerability.(4-24 Weeks)
研究者
相似试验
已完成
不适用
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial HypertensionHypertensionNCT00471003Bayer5,448
已完成
不适用
SAPPORO study to Prove the Effects of telmisartan and valsartan on Early morning blood pressure based on amlodipine treatmentpatients with essential hypertensionJPRN-UMIN000003922SPEED investigators250
已完成
不适用
Assessment of Compliance With Antihypertensive Telmisartan TherapyHypertensionNCT00470886Bayer3,400
已完成
不适用
Micardis® in Patients With Essential HypertensionHypertensionNCT02187705Boehringer Ingelheim1,688
已完成
不适用
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in HospitalsHypertensionNCT02238262Boehringer Ingelheim2,318